Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. - Wikidata - awgldk - TriplyDB

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q38051449

about

Molecularly targeted drugs for metastatic colorectal cancer Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Cost Considerations in the Evaluation and Treatment of Colorectal Cancer.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland.

P2860

Q26828735-7012F729-FB2F-4304-9BDF-02DA929A325F Q34573847-ED864DBB-3EFB-4C1A-A327-AFDBD132601E Q35167535-E079D41F-2AE3-4672-B7C1-3710045A3FA2 Q35173951-4175F5C4-B61B-4A0A-B578-1F9187194148 Q35604265-0BB147E7-40C2-4B62-A24B-DE9453FEE0D4 Q36844535-2BBFC928-3BBC-4A5D-A848-3CBDB05C36EC Q38074913-9A2165D7-BB2D-4EFF-B5BE-ED7E46A23474 Q38076077-34CDF630-B0BA-4A4B-BE94-76C7ED0A888A Q38078288-48A7B666-FC38-4F43-AC28-ABEBC83BAF4C Q38091324-82DE527C-5F80-4645-9826-9AD9D93EEC42 Q38097338-D7EB44F9-815D-42B4-BF7C-822D9BBB276E Q38098104-E2C7F3D7-86AC-4D37-8BFA-7376BBB53541 Q38098483-FC8BF0FD-3DC5-4F6F-A146-4B0D23CF4EBF Q38098484-55027383-6074-41AC-B0DB-521CF917225D Q38101892-AE889487-443A-4BEE-8993-4DF2B98DA286 Q38133381-2AB7C5E4-0D90-463C-8C0D-5A8FA6ABBF04 Q38149091-B84C4F10-DF42-467E-BB86-A85915D79233 Q38544945-5BADE9E2-DE51-4056-BD24-23F7E230679C Q38643555-5B340A32-E82F-4549-B9C9-109D3DFE2BE0 Q39583831-E8488A44-74CA-44B9-BE3A-40885B7FE283

P2860

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q38051449

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

@en

type

label

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

@en

prefLabel

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

@en

P1433

Q38051449-97580C91-0E5F-470C-9ADE-714D6469A60A

P1476

Q38051449-4056490F-485E-4FB6-850E-E803829BDF45

P2093

Q38051449-66973E99-CBEB-49CE-B344-46937DB18871

Q38051449-A2673844-C6FD-43BC-B9FA-C24FF2148C6C

P2860

Q38051449-096529A0-EBF7-4367-BE92-BA1EB2B50EF3

Q38051449-10A8DB83-6F61-465B-8D7A-C8994414CEE7

Q38051449-1B25C937-4B3D-4773-8EA8-5310157537A6

Q38051449-1BCD32AF-E076-4926-81C4-FA1161DC631E

Q38051449-2887BD13-B64A-4AF1-911C-4FE23A6ADC5D

Q38051449-363935C0-D26A-4255-963F-D0C493199BD3

Q38051449-36BB3098-D543-4DDB-A9FF-9A2085D6AB80

Q38051449-42427A7C-E85C-4DD0-BB6E-2CE8862E65EC

Q38051449-5250772C-78FD-4FC7-8A88-1FD33F9D7395

Q38051449-548CD9E3-8191-441A-BDE2-4F5C4113FC05

P2888

Q38051449-6B93CD78-0381-4190-BB89-19376B069331

P304

Q38051449-59845892-FCEE-48FC-B438-015640CB64A9

P31

Q38051449-9CF743B7-CC52-4B25-B54B-6D12EF1737CD

P356

Q38051449-6D24032D-764F-48DA-A38E-15F5DBDC6A17

P433

Q38051449-70F7C14A-A249-4597-8CAE-6585D4D192B2

P478

Q38051449-40489B9B-097D-407E-9A2B-D8E57406AAF1

P50

Q38051449-979FB15B-3421-4051-A095-CF2695175489

P577

Q38051449-1D3822CD-F85C-443A-B091-1B7ABC733CD5

P6179

Q38051449-BB484D3E-618E-4048-A267-5DA7465D189B

P698

Q38051449-F1AD4017-4E8A-42EB-AD34-CE5D5A6060F2

P921

Q38051449-648B5323-897E-4318-8121-B9B9E23EA1FB

Q38051449-EFEE26ED-C81D-4AAE-864F-C9598C6B9F30

P356

11597210-000000000-00000

P1433

PharmacoEconomics

P1476

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

@en

P2093

Matt Stevenson

http://www.w3.org/2001/XMLSchema#string

Sophie Whyte

http://www.w3.org/2001/XMLSchema#string

P2860

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

P2888

11597210-000000000-00000

P304

1119-1132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11597210-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Abdullah Pandor

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039607735

http://www.w3.org/2001/XMLSchema#string

P698

23058097

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer